Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1

Diabetes Care. 2006 Feb;29(2):435-49. doi: 10.2337/diacare.29.02.06.dc05-1267.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amyloid / pharmacology
  • Amyloid / therapeutic use*
  • Blood Glucose / drug effects*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Glucagon-Like Peptide 1 / pharmacology
  • Glucagon-Like Peptide 1 / therapeutic use*
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Islet Amyloid Polypeptide
  • Receptors, Glucagon / therapeutic use*

Substances

  • Amyloid
  • Blood Glucose
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Islet Amyloid Polypeptide
  • Receptors, Glucagon
  • Glucagon-Like Peptide 1